title: A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia.
abstract: BACKGROUND
  Functional dyspepsia is characterized by upper abdominal pain or discomfort.
  
  
  OBJECTIVE
  To assess the benefit of the 5-HT3-receptor antagonist alosetron in a pilot, dose-ranging, placebo-controlled, multicentre, randomized clinical trial.
  
  
  METHODS
  A total of 320 functional dyspepsia patients received placebo (n=81), or alosetron 0.5 mg b.d. (n=77), 1.0 mg b.d. (n=79) or 2.0 mg b.d. (n=83) for 12 weeks, followed by 1 week of follow-up. Primary efficacy was the 12-week average rate of adequate relief of upper abdominal pain or discomfort. Secondary endpoints assessed pain and upper gastrointestinal symptoms.
  
  
  RESULTS
  Twelve-week average rates of adequate relief of pain or discomfort were 46% (95% CI: 37-54%), 55% (95% CI: 46-63%), 55% (95% CI: 47-64%) and 47% (95% CI: 38-55%) in the placebo, 0.5 mg, 1.0 mg and 2.0 mg alosetron groups, respectively. Alosetron 0.5 mg or 1.0 mg showed potential benefit over placebo for early satiety and postprandial fullness. Females showed greater responses compared to males. Patients with adequate relief had significantly (P < 0.001) greater reductions in severity and frequency of functional dyspepsia symptoms than those without adequate relief. Constipation was the most commonly reported adverse event.
  
  
  CONCLUSIONS
  Alosetron showed potential benefit in relieving functional dyspepsia symptoms compared to placebo. Patients with adequate relief of upper abdominal pain or discomfort showed improvements in multiple functional dyspepsia symptoms.
authors: Department of Medicine, University of Sydney, Sydney, Australia.
authors: N J
authors: NJ
authors: Talley
authors: S V
authors: SV
authors: Van Zanten
authors: L R
authors: LR
authors: Saez
authors: G
authors: G
authors: Dukes
authors: T
authors: T
authors: Perschy
authors: M
authors: M
authors: Heath
authors: C
authors: C
authors: Kleoudis
authors: A W
authors: AW
authors: Mangel
mesh_terms: D000284:Administration, Oral; D000328:Adult; D002243:Carbolines / Q000008:administration & dosage / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004415:Dyspepsia / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005765:Gastrointestinal Agents / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy / Q000209:etiology; D010919:Placebos; D012720:Severity of Illness Index; D012737:Sex Factors; D016896:Treatment Outcome
chemical_list: D002243:Carbolines; D005765:Gastrointestinal Agents; D010919:Placebos; C090840:alosetron